Sosei heptares initiates phase 1 trial with novel small-molecule cgrp antagonist under collaboration with biohaven

Tokyo and cambridge, england, june 23, 2021 /prnewswire/ -- sosei group corporation ("the company"; tse: 4565) today announces that the first healthy subject has been dosed with htl0022562 in a phase 1 clinical study. htl0022562 (also known as bhv3100) is a novel, small molecule cgrp* receptor antagonist discovered by sosei heptares and the lead compound in a portfolio of cgrp antagonists licensed to biohaven pharmaceutical holding company ltd.
BHVN Ratings Summary
BHVN Quant Ranking